Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$133.58 USD
+1.19 (0.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $133.46 -0.12 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$133.58 USD
+1.19 (0.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $133.46 -0.12 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
Addus HomeCare's (ADUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Addus HomeCare (ADUS).
The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic
3 MedTech Growth Stocks With Solid Prospects for 2021
by Zacks Equity Research
Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.
Bet on These 5 Low Leverage Stocks to Avoid Portfolio Losses
by Aparajita Dutta
Debt financing is desirable as long as the companies succeed in generating a higher rate of return compared to the interest rate. You may consider adding TITN, SAIA, BCC, ODP, ADUS in your portfolio
Is Addus HomeCare (ADUS) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Addus HomeCare (ADUS).
Quest Diagnostics (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ADUS vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. AMED: Which Stock Is the Better Value Option?
Addus HomeCare Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Addus HomeCare has been struggling lately, but the selling pressure may be coming to an end soon.
3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest
by Debanjana Dey
Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.
Healthcare for Silver Years to Aid Encompass Health (EHC)
by Zacks Equity Research
Encompass Health's (EHC) inpatient rehabilitation and home hospice businesses are poised to grow on the back of aging population.
Encompass Health to Build Rehabilitation Hospital in Illinois
by Zacks Equity Research
Encompass Health (EHC) plans to build a rehabilitation facility in Illinois to serve the local community. The healthcare home will be launched in 2022 spring and complement other units in the area.
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
3 Reasons Growth Investors Will Love Addus HomeCare (ADUS)
by Zacks Equity Research
Addus HomeCare (ADUS) could produce exceptional returns because of its solid growth attributes.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Is Addus HomeCare (ADUS) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Addus HomeCare (ADUS) could produce exceptional returns because of its solid growth attributes.
Top Ranked Momentum Stocks to Buy for January 21st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 21st.
What Makes Addus HomeCare (ADUS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Addus HomeCare (ADUS) have what it takes to be a top stock pick for momentum investors? Let's find out.
DGX or ADUS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DGX vs. ADUS: Which Stock Is the Better Value Option?
3 Reasons Why Addus HomeCare (ADUS) Is a Great Growth Stock
by Zacks Equity Research
Addus HomeCare (ADUS) possesses solid growth attributes, which could help it handily outperform the market.
Addus HomeCare (ADUS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 6.90% and 5.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: NRG, AquaVenture, Addus, Amedisys and Bluerock Residential
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NRG, AquaVenture, Addus, Amedisys and Bluerock Residential
5 Top Stocks to Gain From Fed's Stable Monetary Stance
by Nalak Das
Fed was compelled to reduce it in three consecutive and equal tranches of 25 basis points to sustain the expansion of the U.S. economy.
Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking for a Growth Stock? 3 Reasons Why Addus HomeCare (ADUS) is a Solid Choice
by Zacks Equity Research
Addus HomeCare (ADUS) possesses solid growth attributes, which could help it handily outperform the market.